Advertisement

Document › Details
GlaxoSmithKline plc. (3/1/17). "Press Release: GSK Confirms Closure of Agreement to Divest Anaesthesia Portfolio to Aspen". London.
![]() |
Region | ww excl North America |
![]() |
Organisation | GlaxoSmithKline plc (LSE: GSK, NYSE: GSK) |
Today | GSK plc (LSE: GSK, NYSE: GSK) | |
Group | GSK (Group) | |
Organisation 2 | Aspen Pharmacare Holdings Ltd. | |
![]() |
Product | Ultiva® |
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the closure of an agreement with Aspen (JSE: APN) aligned with GSK’s strategy of simplification through focusing on core therapeutic areas.
GSK has divested its anaesthesia portfolio to Aspen (excluding the US and Canada which had been previously divested) for £180m plus milestones of up to £100m.
Notes to editors:
> GSK’s anaesthesia portfolio consists of Ultiva, Nimbex, Tracrium, Mivacron and Anectine.
> GSK 2016 full year sales of the anaesthesia portfolio were approximately £70 million.
GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.
GSK enquiries:
UK Media enquiries:
Simon Steel
+44 (0) 20 8047 5502
(London)
Anna Carruth
+44 (0) 20 8047 5502
(London)
US Media enquiries:
Sarah Alspach
+1 202 715 1048
(Washington, DC)
Sarah Spencer
+1 215 751 3335
(Philadelphia)
Analyst/Investor enquiries:
Tom Curry
+ 1 215 751 5419
(Philadelphia)
Gary Davies
+44 (0) 20 8047 5503
(London)
James Dodwell
+44 (0) 20 8047 2406
(London)
Jeff McLaughlin
+1 215 751 7002
(Philadelphia)
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2015.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
Record changed: 2023-06-05 |
Advertisement

More documents for GSK (Group)
- [1] LimmaTech Biologics AG. (7/20/23). "Press Release: GSK Grants LimmaTech Biologics License to Develop and Commercialize Shigella Vaccine". Schlieren....
- [2] CureVac N.V.. (1/6/23). "Press Release: CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs". Tübingen & Boston, MA....
- [3] Oncopeptides AB. (1/4/23). "Press Release: Monica Shaw Appointed CEO of Oncopeptides – Jakob Lindberg Assumes Position as Chief Scientific Officer". Stockholm....
- [4] Valneva S.E.. (11/17/22). "Press Release: Valneva Appoints Dipal Patel as Chief Commercial Officer". Saint-Herblain....
- [5] MorphoSys AG. (10/27/22). "Press Release: GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis". Planegg....
- [6] Adaptimmune Therapeutics plc. (10/25/22). "Press Release: Adaptimmune Enhances Its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSK". Philadelphia, PA & Oxford....
- [7] GSK plc. (10/18/22). "Press Release: GSK Announces Expanded Collaboration with Tempus in Precision Medicine to Accelerate R&D". London....
- [8] Pureos Partners AG. (9/28/22). "Press Release: Pureos Partners Welcomes Dr. Veronica Gambillara Fonck as New Partner to Its Investment Team". Pfäffikon....
- [9] GSK plc. (9/22/22). "Press Release: GSK and Spero Therapeutics Announce Exclusive Licence Agreement for tebipenem HBr, a Late-stage Antibiotic that May Treat Complicated Urinary Tract Infections". London....
- [10] GSK plc. (5/31/22). "Press Release: GSK to Acquire Clinical-stage Biopharmaceutical Company Affinivax, Inc.". London....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top